Saturday 17 October 2026
Export RADX’s income statement to Excel — free account
Radiopharm Theranostics Limited - Sponsored ADR
RADX Healthcare Biotechnology
Radiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.
1.03
0.05
−4.63%
Follow RADX
| Jun '26 | Jun '25 | Jun '24 | |
|---|---|---|---|
Piotroski F-Score |
3 | — | — |
Altman Z-Score |
(6.65) | (2.74) | — |
Altman Z″-Score (non-manufacturers) |
(16.22) | (5.54) | (8.32) |
P/FCF ratio |
0.00 | 0.00 | 0.00 |
Beneish M-Score |
(2.62) | 55.66 | — |
P/Operating CF |
0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.03 | 0.00 | 0.00 |
EV/FCF |
0.03 | 0.00 | 0.00 |
Quick Ratio |
1.14 | 2.65 | 1.11 |
Current Ratio |
1.16 | 2.67 | 1.30 |
Net Debt/EBITDA |
0.08 | 0.82 | 0.42 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
0.04 | 0.05 | 0.00 |
Operating CF/Net income |
0.93 | 0.96 | 0.48 |
Capex/Depreciation |
0.00 | 1.15 | 0.00 |
Interest Coverage |
(505.10) | (584.43) | (73.43) |
| (180.13%) | (108.66%) | 0.00% | |
| (79.84%) | (48.10%) | 0.00% | |
ROIC |
(195.15%) | (173.45%) | (336.13%) |
Return on Tangible Assets |
(1,852.14%) | (153.53%) | (899.05%) |
Average Days of Receivables |
2,300.75 | 1,044.76 | 1,204.57 |
Research and Development Expense of Revenue |
1,805.06% | 757.28% | 7,716.62% |
Selling, General and Administrative Expense of Revenue |
672.76% | 455.04% | 5,240.88% |
Intangible Assets out of Total Assets |
0.63 | 0.54 | 0.68 |
Share Based Compensation of Revenue |
86.92% | 52.16% | 882.47% |
Graham Net Nets |
0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% |
Revenue per Share |
0.18 | 0.34 | 0.15 |
Operating CF per Share |
(3.50) | (3.42) | (11.70) |
Capex per Share |
0.00 | 0.28 | 0.00 |
Free Cash Flow per Share |
(3.50) | (3.14) | (11.70) |
Cash per Share |
0.27 | 2.72 | 9.46 |
Shareholders Equity per Share |
1.48 | 4.00 | 13.93 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
1.48 | 4.00 | 13.93 |
Free Cash Flow |
(35.82) | (21.79) | (15.07) |
Working Capital |
2.06 | 16.14 | 3.46 |
Capital Expenditures |
— | 1.94 | — |
Net Current Asset Value |
(10.78) | (2.43) | (14.32) |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | (0.82) | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
58.68 | 48.58 | 51.38 |
Cash ROIC |
(199.47%) | (46.74%) | (50.03%) |
Accounts Receivable Turnover |
0.20 | 0.64 | 0.00 |
Accounts Payable Turnover |
0.26 | 0.35 | — |
Inventory Turnover |
0.00 | 0.00 | — |
Average Days of Payables |
1,534.88 | 948.60 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | — |
Average Receivables |
9.29 | 3.69 | — |
Average Payables |
6.60 | 6.58 | — |
Average Assets |
48.41 | 51.62 | — |
Average Common Equity |
21.46 | 22.85 | — |
Columns are period end dates · fundamentals updated 16 Oct 2026